Status:
UNKNOWN
A Study of TL-925 for the Treatment of Allergic Conjunctivitis
Lead Sponsor:
Telios Pharma, Inc.
Conditions:
Allergic Conjunctivitis
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
In this prospective Phase 2, single-center, randomized, double-masked, placebo-controlled study, approximately 70 subjects with allergic conjunctivitis will be randomized 1:1 to receive either TL-925 ...
Eligibility Criteria
Inclusion
- Individuals aged 18 years or older
- Female subjects of childbearing potential and their male partners must both use a highly effective contraception method during the study.
- Documented history of ocular allergies and a positive skin test reaction to a seasonal (grass, ragweed, tree pollen) or perennial (cat dander, dog dander, dust mites, cockroach) allergen as confirmed by an allergic skin test conducted at Visit 1 or within the past 60 months.
- Calculated best-corrected visual activity of 0.7 LogMAR or better
- Positive bilateral CAC reaction
Exclusion
- Any systemic or ocular disease currently producing ocular redness and/or ocular discomfort, or that may interfere with the conduct of the study.
- Any ocular surgical intervention within the last 3 months OR refractive surgery within the last 6 months
- Any ongoing ocular infection (bacterial, viral or fungal)
Key Trial Info
Start Date :
November 1 2023
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
January 1 2024
Estimated Enrollment :
70 Patients enrolled
Trial Details
Trial ID
NCT06153342
Start Date
November 1 2023
End Date
January 1 2024
Last Update
December 1 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Andover Eye Associates
Andover, Massachusetts, United States, 01810